Anticancer Drugs Olaparib Oncology Pharmacology Physiotherapy

Olaparib (Clinical Trials Experience-3)

In this article, we will discuss Olaparib (Clinical Trials Experience-3). So, let’s get started.

Dose interruptions due to an adverse reaction of any grade occurred in 45% of patients receiving Olaparib and 18% of those receiving placebo; dose reductions due to an adverse reaction occurred in 27% of Olaparib patients and 3% of placebo patients. The most frequent adverse reactions leading to dose interruption or reduction of Olaparib were anemia (22%), neutropenia (9%), and fatigue/asthenia (8%). Discontinuation occurred in 11% of Olaparib patients and 2% in placebo patients.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.